DRTC Featured Press

First Islet Workshop draw international audience

Islet-poster_edited-1.jpg

More than 200 investigators from across the globe who specialize in islet biology, the study of hormone-producing cell clusters in the pancreas known as islets, recently gathered in Nashville to share knowledge and present the challenges and successes of their work during the first Islet Biology Workshop at Vanderbilt.

Read more >>


Team's findings could spur new treatments for type 2 diabetes

Wasserman-Lab_AR2018-342_edited-1.jpg

Research on how the diabetes drug metformin blocks glucose production by the liver by David Wasserman, PhD, left, Curtis Hughey, PhD, Louise Lantier, PhD, and colleagues could lead to new ways to treat type 2 diabetes.

Read more >>


NIDDK director lauds medical student research contributions

SA-NIDDK-director-JH_edited-1.jpg

Griffin Rodgers, MD, director of the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), presented a lecture and observed poster presentations by several medical students including, from left, Charles Akiona from University of Hawaii, Kunal Sampat from Midwestern University Arizona College of Osteopathic Medicine and Monica Choo from University of Michigan. (photo by Joe Howell)

Read more >>


METP Training Grant Renewal

Financial_Report-512.png
 

The Molecular Endocrinology Training Program (METP) at Vanderbilt University, led by Richard O’Brien, PhD, Maureen Gannon, PhD, Owen McGuinness, PhD and Brian Wadzinski, PhD, has been awarded their 5-year competitive renewal training grant to fund the program. The goal of the METP is to provide resources for training researchers in molecular endocrinology, and provide support for research labs working in areas such as signal transduction, the regulation of gene expression, beta-cell development, and metabolic regulation. This program has been supported by this training grant for 31 years.

Molecular Endocrinology Training Program >>


Team explores diabetes drug’s ability to treat RSV infection

RSV-team-JH0002_edited-1.jpg

A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.

Read more >>